Drug Profile

LY 2880070

Alternative Names: LY2880070

Latest Information Update: 16 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Esperas Pharma
Class Antineoplastics
Mechanism of Action Checkpoint kinase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Solid tumours

Most Recent Events

14 Apr 2025 Esperas Pharma completes a phase Ib/IIa trial in Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Canada, Poland, Croatia (PO) (NCT02632448)
09 Sep 2022 Efficacy and safety data from a phase I/II trial in Soild tumours presented at the 47^th European Society for Medical Oncology Congress (ESMO 2022)
02 Aug 2019 Phase I/II development is ongoing Canada

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com